Evidence map›Paper›PMID 40539343›Full record

ReviewCurrent pharmaceutical design2025

An Updated Review Deciphering the Inhibitory Potential of Erianin via Targeting Several Dysregulated Oncogenes in Several Human Carcinomas.

Pratibha Pandey, Seema Ramniwas, Lalji Baldaniya, G PadmaPriya, Khushboo Rani, Shivang Mishra, Irwanjot Kaur, Shivam Pandey, Sorabh Lakhanpal, Fahad Khan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pratibha PandeyCentre for Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
Seema RamniwasUniversity Centre of Research and Development, University Institute of Biotechnology, Chandigarh University Gharuan, Mohali, Punjab, India.
Lalji BaldaniyaMarwadi University Research Center, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Marwadi University, Rajkot, 360003, Gujarat, India.
G PadmaPriyaDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Khushboo RaniDepartment of Pharmacy, Chandigarh Pharmacy College, Chandigarh Group of Colleges, Jhanjeri, Mohali, 140307, Punjab, India.
Shivang MishraNIMS Institute of Pharmacy, NIMS University Rajasthan, Jaipur, India.
Irwanjot KaurDepartment of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan, 303012, India.
Shivam PandeySchool of Applied and Life Sciences, Uttaranchal University, Dehradun, India.
Sorabh LakhanpalSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
Fahad KhanCenter for Global Health Research Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous edible vegetables and fruits possess plant-based compounds with enormous anticarcinogenic attributes, including phenolic, vitamins, and alkaloid compounds. Cancer therapies mainly encompass surgery, chemotherapy, and radiation therapy, sometimes accompanied by rapid recurrence and significant side effects. Consequently, elucidating efficacious chemotherapeutic procedures are needed to diminish the likelihood of recurrence and metastasis. Erianin (Shihu, Traditional Chinese Medicine), a naturally occurring compound derived from Dendrobium chrysotoxum Lindl., has been documented to possess anticancer and antioxidative properties. This review presented an overview of Erianin's (ER) involvement in cancer and elucidated the molecular mechanisms underlying its anticancer effect via regulating signaling pathways, including PI3K/AKT, MEK, JNK, NRF2/PLOOH, JAK/STAT3, GSK3β, and NLRP3/ROS pathways. All these mechanisms ultimately induce apoptosis via targeting mainly invasion, migration, and angiogenesis. This review is thus intended to include all possible recent progress in the anticancer efficacy of erianin and to justify the necessity for further investigation into its anticancer properties in the future.

Indexed as

Antineoplastic AgentsAntineoplastic Agents, PhytogenicBibenzylsNeoplasmsOncogenesAnimalsHumansPhenolSignal TransductionAntineoplastic AgentsAntineoplastic Agents, PhytogenicBibenzylsErianinPhenolcancerErianinnatural productoncogenessignaling pathwaytraditional Chinese medicine.

Identifiers

PMID40539343

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.